Struck R F, Dykes D J, Corbett T H, Suling W J, Trader M W
Br J Cancer. 1983 Jan;47(1):15-26. doi: 10.1038/bjc.1983.2.
Isophosphoramide mustard was synthesized and was found to demonstrate activity essentially comparable to cyclophosphamide and ifosfamide against L1210 and P388 leukaemia. Lewis lung carcinoma, mammary adenocarcinoma 16/C, ovarian sarcoma M5076, and colon tumour 6A, in mice and Yoshida ascitic sarcoma in rats. At doses less than, or equivalent to, the LD10, isophosphoramide mustard retained high activity against cyclophosphamide-resistant L1210 and P388 leukaemias, but was less active against intracerebrally-implanted P388 leukaemia while cyclophosphamide produced a 4 log10 tumour cell reduction. It was also less active (one log10 lower cell kill) than cyclophosphamide against the B16 melonoma. Metabolism studies on ifosfamide in mice identified isophosphoramide mustard in blood. In addition, unchanged drug, carboxyifosfamide, 4-ketoifosfamide, dechloroethyl cyclophosphamide, dechloroethylifosfamide, and alcoifosfamide were identified. The latter 4 metabolites were also identified in urine from an ifosfamide-treated dog. In a simulated in vitro pharmacokinetic experiment against L1210 leukaemia in which drugs were incubated at various concentrations for various times, both 4-hydroxycyclophosphamide and isophosphoramide mustard exhibited significant cytoxicity at concentration times time values of 100-1000 micrograms X min ml-1, while acrolein was significantly cytotoxic at 10 micrograms X min ml-1. Treatment of mice with drug followed by L1210 cells demonstrated a shorter duration of effective levels of cytotoxic activity for isophosphoramide mustard and phosphoramide mustard in comparison with cyclophosphamide and ifosfamide. Isophosphoramide mustard and 2-chloroethylamine, a potential hydrolysis product of isophosphoramide mustard and carboxyifosfamide, were less mutagenic in the standard Ames test than the 2 corresponding metabolites of cyclophosphamide [phosphoramide mustard and bis(2-chloroethyl)amine].
异环磷酰胺氮芥被合成出来,结果发现它对L1210和P388白血病的活性与环磷酰胺和异环磷酰胺基本相当。对小鼠的Lewis肺癌、乳腺腺癌16/C、卵巢肉瘤M5076和结肠肿瘤6A以及大鼠的吉田腹水肉瘤均有活性。在剂量小于或等于LD10时,异环磷酰胺氮芥对耐环磷酰胺的L1210和P388白血病仍保持高活性,但对脑内植入的P388白血病活性较低,而环磷酰胺可使肿瘤细胞减少4个对数级。它对B16黑色素瘤的活性也比环磷酰胺低(细胞杀伤低1个对数级)。对小鼠体内异环磷酰胺的代谢研究在血液中鉴定出了异环磷酰胺氮芥。此外,还鉴定出了未变化的药物、羧基异环磷酰胺、4-酮基异环磷酰胺、去氯乙基环磷酰胺、去氯乙基异环磷酰胺和醇基异环磷酰胺。在一只经异环磷酰胺治疗的狗的尿液中也鉴定出了后4种代谢产物。在一项针对L1210白血病的模拟体外药代动力学实验中,将药物在不同浓度下孵育不同时间,4-羟基环磷酰胺和异环磷酰胺氮芥在浓度时间值为100 - 1000微克·分钟/毫升时均表现出显著的细胞毒性,而丙烯醛在10微克·分钟/毫升时具有显著的细胞毒性。用药物处理小鼠后再接种L1210细胞,结果表明与环磷酰胺和异环磷酰胺相比,异环磷酰胺氮芥和磷酰胺氮芥的细胞毒性活性有效水平持续时间较短。在标准的艾姆斯试验中,异环磷酰胺氮芥和2-氯乙胺(异环磷酰胺氮芥和羧基异环磷酰胺的潜在水解产物)的致突变性低于环磷酰胺的2种相应代谢产物[磷酰胺氮芥和双(2-氯乙基)胺]。